NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data
NeOnc raises $15 million at-market as NEO100 Phase 2a results beat a prespecified benchmark and it prepares for an FDA Type B meeting.
Rhea-AI Summary
NeOnc Technologies Holdings (NTHI) announced a $15 million registered direct offering priced at-the-market under Nasdaq rules, involving new and existing healthcare-focused institutional investors.
The deal covers 3.57 million shares, or pre-funded warrants in lieu of shares, plus warrants for another 3.57 million shares with a $4.20 exercise price, with closing expected tomorrow subject to customary conditions. The company highlights that this structure provides capital without a headline discount to market price. The financing coincides with positive NEO100 Phase 2a data in recurrent or progressive Grade III/IV IDH1-mutant glioma, where 6‑month progression-free survival reached 48.9% versus a 20% prespecified benchmark (p=0.0047), median overall survival was 26.09 months, and 86.7% of patients were alive at six months. NeOnc plans to seek a Type B FDA meeting on a potential registrational pathway and reports ongoing NEO212 development and recent insider share purchases by its CEO and a director.
Positive
- $15 million registered direct offering priced at-the-market under Nasdaq rules
- Offering includes 3.57 million shares or pre-funded warrants plus 3.57 million warrants at $4.20
- NEO100 Phase 2a 6-month PFS 48.9% vs 20% benchmark (p=0.0047)
- NEO100 median overall survival 26.09 months; 6‑month OS 86.7%
- CEO open-market buying exceeds $500,000, including 15,000 shares (~$58,600) in August
- Director bought 36,259 total shares on August 14 and 17
- NEO212 Phase 1 completed with recommended Phase 2 dose of 610 mg
- UAE IND approvals granted for NEO100 and NEO212, adult and pediatric programs
Negative
- Financing implies potential dilution from 3.57 million new shares plus 3.57 million warrant shares
- NEO100 Phase 2a described as small and open-label, limiting robustness of evidence
- Further clinical work, regulatory review and a potential registrational trial still required before any approval
News Explained
The financing is not yet closed; completion would add capital but dilute existing ownership through new and potentially warrant-linked shares.
NeOnc has announced the financing, but it remains expected to close tomorrow rather than completed; if it closes, the new shares or pre-funded warrants would increase the share count and reduce existing holders’ percentage ownership, while the separate warrants could add further shares if exercised.
At-market pricing avoids the company’s stated headline discount, but it does not remove the ownership dilution created by issuing securities that can become shares.
The announced
The next specific checkpoint is closing tomorrow, which remains subject to customary conditions; until then, the announced financing has not become completed cash or share issuance.
Sources and calculations
- NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data (2026-09-09)
- Dilution (2026-07-17)
- Pre-funded warrant (2026-07-17)
- NeOnc second-quarter fundamentals (2026Q2)
- Offering gross against the last reported quarterly operating outflow, in days at that rate $15,000,000 / ($4,765,181 / 91) = 286.5 days
- Available liquidity against the last reported quarterly operating outflow, in days at that rate $1,973,420 / ($4,765,181 / 91) = 37.7 days
Details
Market reaction after registered direct offering: NTHI -10.44%
Following this news, NTHI has declined 10.44%, reflecting a significant negative market reaction. Our momentum scanner has triggered 7 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $3.65. Trading volume is exceptionally heavy at 5.9x the average, suggesting significant selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Offering Size
- $15 million
- Registered direct offering priced at-the-market
- Shares Offered
- 3.57 million shares
- Shares or pre-funded warrants in lieu of shares
- Warrant Coverage
- 3.57 million shares
- Warrants attached to the offering
- Warrant Exercise Price
- $4.20
- Exercise price per warrant share
- Six-Month Progression-Free Survival
- 48.9%
- NEO100 Phase 2a study
- Prespecified Benchmark
- 20%
- NEO100 Phase 2a study
- P-value
- 0.0047
- NEO100 Phase 2a study
- Median Overall Survival
- 26.09 months
- Patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma
Historical Context
-
Phase 2a data reported 48.9% six-month progression-free survival versus 20% benchmark
-
Phase 2a results exceeded the prespecified progression-free survival benchmark
-
Company highlighted existing $75 million at-the-market equity facility as financing tool
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
registered direct offering financial
pre-funded warrants financial
p-value technical
type b meeting regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) is entering a potentially important new phase with fresh institutional capital, encouraging Phase 2a data and a string of open-market insider purchases. The company announced a
The financing structure itself deserves attention. An at-the-market-priced registered direct can be considerably more attractive to existing shareholders than the deeply discounted financings frequently seen in small-cap biotechnology, where companies may issue stock well below the prevailing market price to entice investors. NTHI's transaction was instead priced at the market under Nasdaq rules, with warrants attached, giving the company capital without the headline discount that often accompanies distressed or highly dilutive biotech financings. The quality of the financing also removes a major cornerstone of the shorters’ thesis.
NeOnc is raising that money at a particularly interesting time. On August 12, the Company reported positive topline results from its NEO100 Phase 2a study in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. Six-month progression-free survival was
The Phase 2a study was small and open-label, and additional clinical work, regulatory review and potentially a registrational trial remain ahead, as NeOnc plans to request a Type B meeting with the FDA to discuss a potential registrational pathway for NEO100. That meeting could become the next major catalyst because it may help establish what additional evidence regulators would require to move the program toward a potential approval.
The company is also developing NEO212, which completed Phase 1 and established a recommended Phase 2 dose of 610 mg. In June, NeOnc announced UAE IND approvals for NEO100 and NEO212, covering adult and pediatric development programs. NEO100 is an intranasal formulation of purified perillyl alcohol designed around the difficult challenge of delivering therapeutics to the central nervous system. NeOnc's broader NEO platform is intended to address the blood-brain barrier and other challenges associated with CNS drug delivery.
Then there is the insider activity. CEO Amir Heshmatpour has repeatedly been buying NTHI shares in the open market, including 15,000 shares in August. Those purchases represented approximately
That combination, new institutional financing, clinical data that exceeded the study's prespecified benchmark, an upcoming FDA regulatory discussion and substantial insider buying, creates a much more consequential setup than a simple biotech financing story.
The market's next question is increasingly straightforward: Can NeOnc turn its Phase 2a signal into a credible registrational strategy? If the FDA provides a pathway that management and investors view as achievable, the Company's latest financing could prove strategically important.
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
FAQ
What are the key terms of NeOnc's new financing?
The company entered a $15 million registered direct offering priced at-the-market under Nasdaq rules with new and existing healthcare-focused institutional investors. The deal covers 3.57 million shares, or pre-funded warrants in lieu of shares, plus warrants for another 3.57 million shares with a $4.20 exercise price. Closing is expected the day after the announcement, subject to customary conditions.
What efficacy results were reported from the NEO100 Phase 2a glioma study?
In patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma, NEO100 achieved 6‑month progression-free survival of 48.9%, compared with a prespecified 20% benchmark, with a reported p-value of 0.0047. Median overall survival was 26.09 months, and 86.7% of patients were alive at six months. Five of 24 patients remained on treatment, including one partial responder beyond 114 days.
What are NeOnc's next regulatory plans for NEO100?
NeOnc plans to request a Type B meeting with the FDA to discuss a potential registrational pathway for NEO100. The company indicates that additional clinical work, regulatory review and possibly a registrational trial are expected before any potential approval can be pursued.
What is the status of NeOnc's NEO212 program?
NEO212 has completed a Phase 1 study and established a recommended Phase 2 dose of 610 mg. In June, NeOnc also received UAE IND approvals for NEO212, alongside NEO100, covering adult and pediatric development programs.
What is NEO100 and how is it administered?
NEO100 is described as an intranasal formulation of purified perillyl alcohol designed to address the challenge of delivering therapeutics to the central nervous system. It is part of NeOnc's broader NEO platform, which is intended to tackle the blood-brain barrier and other central nervous system drug delivery issues.